Objective To investigate the clinical features of Henoch-Schonlein purpura nephritis(HSPN) and the clinical significance of plasma endothelin-1(ET-1) in HSPN.Methods The epidemiology and clinical characteristics were retrospectively analyzed in 84 patients admitted to our hospital from January 2000 to March 2005.The changes of ET-1 were measured in 84 patients and 16 controls by using radioimmunologic assay.Results The age of onset in HSPN was 5-10 years and the corresponding patients occupied 90.6%.The majority of HSPN cases(80.32%) occurred from September to March of the second year.Infection was still the main occasion factor(40.57%),and the mistaken diagnosis at rate of 33.33% as acute gastricism and appendicitis when gastrointestinal sign appeared earlier than the typical purpura.The nephritic syndrome was the most constant clinical manifestation(47.63%).The pathological type of grade Ⅱ was 37.84%,grade Ⅲ 56.40%.The level of plasma ET-1 in patients was more higher than that of normal controls.The level of plasma ET-1 had a positive correlation with plasma urea nitrogen and creatinine(r=0.584,0.523,P

Objective To evaluate the predictive value of admission blood glucose level for the mortality within 30-day and major adverse cardiac events(MACE) rate in patients with ST-segment elevation acute myocardial infarction (STEMI). Methods An observational analysis of 7446 Chinese STEMI patients from a global randomized controlled trials of cases recruited within 12 hours of symptom onset was carried out. According to the levels of admission glucose (hyperglycemia was defined as admission glucose>10 mmol/L) and known diagnosis of diabetes mellitus (DM) ,these patients were divided into four groups, Ⅰ :no DM and normal glucose group (control group) ; Ⅱ : DM but normal glucose group; Ⅲ : no DM and hyperglycemia group; and Ⅳ: DM and hyperglycemia group. Results Admission hyperglycemia was associated with a significantly higher 30-day mortality rate (group Ⅲ 17. 1% vs group I 8.6%, group Ⅳ 18.6% vs group Ⅰ 8. 6%, P<0.001) and also an increased incidence of MACE (group Ⅲ36. 3% vs group Ⅰ 21.6%, group Ⅳ 38. 8% vs group Ⅰ 21.6%, P<0.001). However, DM without admission hyperglycemia did not increase the 30-day mortality (group Ⅱ 11.6% vs group Ⅰ 8. 6%, P = 0.096). Multivariate logistic regression analysis showed that compared with group Ⅰ patients, group Ⅲ and group Ⅳ had a risk of death of 1.51 fold(OR 1.51,95% CI 1.22-1.87,P<0.001) and 1.83 fold(OR 1.83,95% CI 1.40-2. 39, P<0.001) respectively; hyperglycemia was an independent predictor of 30-day mortality and an increase of 1 mmol/L in glucose level was associated with a 5% increase of mortality risk (OR 1.05,95% CI 1.04-1.07,P<0.001), but DM without hyperglycemia was not so (OR 1.11,95% CI 0. 87-1.42, P =0. 412). Conclusions The rates of 30-day mortality and cardiovascular events are significantly higher in STEMI patients with acute hyperglycemia than in patients without. Hyperglycemia on admission is an independent risk factor for the short-term outcome of STEMI, but diabetes mellitus without hyperglycemia isv not associated with the short-term mortality.

Objective: To explore the relationship between serum sodium level and early prognosis in patients with acute ST-elevation myocardial infarction (STEMI). Methods: A total of 7461 STEMI patients within 12h of onset who matched the diagnostic standard of European society of cardiology and American college of cardiology were retrospectively studied. According to serum sodium levels within 24h of admission, the patients were categorized into 3 groups: Serum sodium≥135 mmol/L group, Serum sodium 130-134 mmol/L group and Serum sodium<130 mmol/L group. The baseline condition, 30-day mortality with other adverse events and the effect of neuroendocriology inhibitor treatment were compared among 3 groups; their relationships to serum sodium level were analyzed. Results: Serum sodium<130 mmol/L group had the higher 7-day and 30-day mortality than the other 2 groups, both P<0.001; compared with Serum sodium≥135 mmol/L group, Serum sodium<130 mmol/L group presented the higher occurrence rates of 30-day cardiac shock, heart failure (HF) and life-threatening arrhythmia, P<0.001. With adjusted affecting factors of age, diuretic and reperfusion treatments, serum sodium<130 mmol/L was still related to 7-day and 30-day mortality (OR=1.69 and OR=1.57). Both single and multivariable analysis indicated that serum sodium<130 mmol/L was related to cardiac shock (OR=1.75 and OR=1.64), HF (OR=1.42 and OR=1.30) and life-threatening arrhythmia (OR=1.53 and OR=1.34). In all 3 groups, the patients using ACE inhibitor, β-blocker or both medications had reduced 30-day mortality than those without such medication, allP<0.001; the reduction was more obvious in Serum sodium<130 mmol/L group than the other 2 groups,P<0.001. Conclusion: Serum sodium level<130 mmol/L within 24h of admission was the risk factor for the early stage main adverse events as mortality, cardiac shock, HF and life-threatening arrhythmia in acute STEMI patients.

Objective To provide scientific evidences for Zika virus detection by clarifying the means by which Zika virus was discharged and the duration of corresponding processes. Methods Various samples of Zika cases were collected at different times and detected by using real-time RT-PCR. The positive samples were inoculated into cells and suckling mice through intracranial injection. The whole genome se-quences of those isolated Zika virus strain were sequenced and the results were further analyzed by comparing with the sequences of Zika virus from GenBank. Results The positive rates of Zika virus in urine, saliva and serum samples were 82. 4% (14/17), 82. 4% (14/17) and 52. 9% (9/17) respectively. The longest period of detected presence of Zika virus was found in urine samples amongst the three types of samples, fol-lowed by saliva and serum samples. Six Zika virus strains were isolated from 9 positive serum samples. Phy-logenetic analysis showed that the six genomes of Zika virus all belonged to Asia lineage, but located in two branches by Samoa and Venezuela strains. Conclusion This study indicated that urine, saliva and serum all could be used as the samples for routine detection of Zika virus. Urine and saliva samples showed higher detection rates of Zika virus RNA in comparison to serum samples, while Zika virus could be easily isolated from positive serum samples. Suckling mice were better for Zika virus isolation than cell lines.

Objective To establish a method for the isolation of Zika virus and to gather experi-ences for viral isolation. Methods Suckling mice at age 1-3 days were inoculated with serum samples posi-tive for Zika virus through intracranial injection. All mice were sacrificed 6 days after the injection. Viral nu-cleic acids were extracted from brain, heart, liver, spleen, lung, kidney, muscle, skin and intestine tissue samples and analyzed by real-time RT-PCR. The supernatants of brain tissues positive for Zika virus were used for subculturing. Nested PCR was performed to amplify the NS5 gene of the isolated virus. The se-quences of NS5 gene were analyzed by using MEGA6. 0 software. Results All of the tissue samples were positive for Zika virus. Higher viral loads were detected in heart and brain tissue samples with cycle thresh-old (Ct) values of 24. 4 and 25. 3, respectively. The second generation of Zika virus was identified in suck-ling mice brain tissues 2 days after infection by using real-time RT-PCR. The amplified product of nested PCR was 972 bp in length. Sequencing analysis showed that the isolated Zika virus ( GDZ16002 strain) be-longed to the Asian lineage. Conclusion A strain of Zika virus was successfully isolated in China by using intracranial injection via a suckling mouse model. The isolated Zika virus belonged to the Asian lineage.

Objective To analyze the molecular characteristic and trace the resource of dengue virus in Zhuhaidistrict of Guangzhou during 2012-2015.Methods Collected the cases data of dengue fever in Zhuhai district from 2012-2015 and analyzed the epidemical characteristic.DENV strains were isolated by C6/36 cells,the E gene was amplified from the positive specimen by RT-PCR.The PCR products were sequenced and then analyzed by bio-information software.Results Total of 6 260 DENV infection cases were reported,and the cases happened in every age group;57.78％ of the cases occurred in October.16 virus strains were isolated from 48 samples and the whole E genes were successfully amplified,the virus strains from 2013 and 2014 were the same one and the nucleotide sequence 99.93％ identify with DENV-1 in 2009.Phylogenetic analysis showed that DENV-1 belonged to the G1 genotype,genetically close to the strains from Thailand;strains from 2015 were the same one and belonged to the Cosmopolitan genotype of DENV-2,most similar with the strains from India.Conclusions The DENV-1 outbreak in Haizhu district of Guangzhou during 2012-2015 were belonged to G1 that originated from Thailand and might indigenous in 2009;DENV-2 was belonged to Cosmopolitan genotype which was imported.

Objective: To explore the occurrence of cognitive impairment in Chinese heart failure (HF) patients and it's impact on prognosis. Methods: In this prospective observational study, a total of 990 HF patients were enrolled from 24 hospitals in China during December 2012 to November 2014. All patients were administrated with the interview-format Montreal Cognitive Assessment (MoCA), according to which they were divided into MoCA<26 (with cognitive impairment) group and MoCA≥26 (without cognitive impairment) group. Baseline data were collected and a 1-year follow up was carried out. Univariate and multivariate logistic or Cox regression were performed for 1-year outcomes. Results: Cognitive impairment was evidenced in 628 patients (63.4%) and they were more likely to be older, female, and with higher proportion of New York Heart Association(NYHA) class Ⅲ-Ⅳ, chronic obstructive pulmonary disease (COPD), ischemic heart disease, while body mass index (BMI), education level, and medical insurance rate were lower (all P<0.05) as compared to patients in MoCA≥26 group. The rate of percutaneous intervention, device implantation, cardiac surgery and evidence-based medications were significantly lower in MoCA<26 group than in MoCA≥26 group (all P<0.05). During the 1-year follow up, patients in the MoCA<26 group had higher all-cause mortality (10.2%(64/628) vs. 2.2%(8/362), P<0.01), cardiovascular mortality (5.9%(37/628) vs. 0.8%(3/362), P<0.01) and major adverse cardiac and cerebrovascular events (MACCE) (9.6%(60/628) vs. 2.5%(8/362), P<0.01) than patients in the MoCA≥26 group. In univariate regression, MoCA<26 was associated with increased all-cause mortality (HR(95%CI):4.739(2.272-9.885), P<0.01), cardiovascular mortality (HR(95%CI):7.258(2.237-23.548), P=0.001) and MACCE (OR(95%CI):4.143(2.031-8.453), P<0.01). After adjustment by multivariate regression, MoCA<26 was indicated as an independent risk factor for all-cause mortality (HR(95%CI): 6.387(2.533-16.104), P<0.01), cardiovascular mortality (HR(95%CI): 10.848(2.586-45.506), P=0.001) and MACCE (OR(95%CI): 4.081(1.299-12.816), P=0.016), while not for re-hospitalization for HF (OR(95%CI):1.010(0.700-1.457), P=0.957). Conclusions Cognitive impairment is common in HF patients,and it is an independent prognostic factor for 1-year outcomes. Routine cognitive function assessment and active intervention are thus recommended for HF patients.

Objective This retrospective study is performed to analyze the epidemiological and clinical features of patients with infective endocarditis (IE) hospitalized in Fuwai Cardiovascular Hospital during the latest 7 years.Methods This retrospective study included a cohort of 368 infective endocarditis patients hospitalized in Fuwai Hospital form August 2005 to August 2012.Predisposing cardiac diseases,causative organisms,clinical features and outcomes were analyzed.Risk factors related to outcome including NYHA classes,causative organisms and complications,were evaluated.Results Among the IE patients,6.8％ (25/368) patients had rheumatic heart diseases 31.8％ (117/368) had congenital heart diseases,22.8％ (84/368) were post-PCI or operative endocarditis and IE developed in 14.1％ (52/368) patients without previous cardiac diseases.Blood culture positive rate was 46.2％ (170/368).Streptococci viridians [27.6％ (47/170)]were the most common causative organisms,followed by coagulase-negative staphylococci [15.9％ (27/170)].Fever and cardiac murmur were the most common clinical presentations.Congestive heart failure was the most common complication [87.8％ (323/368)].Systemic and pulmonary embolism occurred in 16.0％ patients,80.9％ IE was detected by echocardiography.In-hospital mortality rate was 6.7％,mostly due to refractory congestive heart failure and sepsis.Subgroup analysis showed that incidence of post-PCI or operative endocarditis was significantly higher in IE patients hospitalized after 2009 compared to IE patients hospitalized before 2009 (27.5％ vs.19.2％,P ＜ 0.05).Higher incidence of staphylococcal infection was evidenced in mechanical valves than in native valves(44.4％ vs.19.8％,P ＜ 0.05).Conclusion During the past decade,there is a significant change on epidemiology and clinical features of IE in China.Incidence of post-surgical and interventional IE increased significantly.Staphylococcal and Gram negative bacilli infection are major pathorganisms of endocarditis of mechanical valves.Due to the lower positive rate of blood culture,echocardiography serves as the most important diagnostic tool for infective endocarditis.

Objective This analysis was performed to evaluate the efficacy in stroke prevention and safety of dabigatran in Chinese nonvalvular atrial fibrillation (NVAF) patients enrolled in RE-LY trial.Methods RE-LY was an prospective,open-label,randomized,multicenter study.From March 2006 to March 2009,541 atrial fibrillation patients at risk of stroke were recruited from 13 medical centers in China.Patients randomly received,in a blinded fashion,fixed doses of dabigatran-110 mg or 150 mg twice daily or,in an unblinded fashion,adjusted-dose warfarin.The primary efficacy endpoint was stroke or systemic embolism.The primary safety endpoint was major bleeding.Results The incidence of stroke in the Chinese subpopulation was 1.94％ per year(7 cases) in the group that received 110 mg of dabigatran (dabigatran 110) and 1.10％ per year (4 cases) in the group that received 150 mg of dabigatran (dabigatran 150),as compared with 2.87％ per year (10 cases) in warfarin group.Incidence of ischemic stroke was 1.11％ per year(4 patients) in dabigatran 110 group,0.82％ per year(3 cases) in dabigatran 150 group and 2.01％ per year(7 patients) in warfarin group.Incidence of hemorrhagic stroke was 0.28％per year(1 case) in dabigatran 110 group,0.27％ per year(1 case) in dabigatran 150 group and 0.57％per year(2 cases) in warfarin group.All-cause mortality was similar among the three treatment groups:3.33％ per year (12 cases) in dabigatran 110,2.19％ per year(8 cases) in dabigatran 150 and 2.58％per year(9 cases) in warfarin group.Incidence of major bleeding event was 0.56％ per year(2 cases) in both dabigatran groups,as compared with 1.43％ per year(5 cases) in warfarin group.Gastrointestinal disorders such as dyspepsia occurred in 12.8％ patients of both dabigatran groups,and in 5.6％ patients of warfarin group.Conclusions Despite the descriptive statistical analysis in nature of present study due to the limited number of subjects,our subgroup analysis implies that like warfarin,dabigatran is efficacious and safe for thromboembolism prevention in Chinese patients with atrial fibrillation at risk of stroke.Clinical Trail Registry National Institutes of Health (http://www.clinicaltrials.gov),CT00262600.

Objectives:To understand the differences in clinical characteristics, treatment status, and prognosis between outpatient and inpatient heart failure patients in the real world.Methods:A prospective, multicenter registration study was conducted to select 972 outpatient or inpatient heart failure patients from 24 different regions and levels of hospitals in China from December 2012 to November 2014. Demographic and clinical data, as well as treatment status, were collected and followed up at 1 year. The difference in medication treatment status between baseline and 1-year follow-up was compared using McNemar paired χ 2 test. Pearson χ 2 test was used to compare the differences in clinical data, treatment status, and outcomes between outpatient and inpatient patients. Results:There were 610 outpatient patients (62.8%), and the proportion of outpatient patients under 65 years old was higher than that of hospitalized patients [44.9%(274/610) vs 35.1%(127/362), P<0.05]. The proportion of NYHA grade Ⅲ/Ⅳ patients was as high as 50.8%(310/610), and 92.5%(564/610) of outpatient patients had difficulty breathing while walking uphill. 27.9%(170/610) of outpatient patients had jugular vein pressure greater than 6 cmH 2O, and 24.3%(148/610) of outpatient patients had pulmonary moist rales. There was no significant difference in the main causes of heart failure between outpatient and inpatient patients ( P=0.063), with ischemic cardiomyopathy being the main cause. At baseline, the use of beta blockers in outpatient patients was higher than that in hospitalized patients [63.0%(384/610) vs 54.4%(197/362), P<0.05], while the use of diuretics and aldosterone receptor antagonists was lower than that in hospitalized patients [53.1%(324/610) vs 72.1%(261/362), 49.5%(302/610) vs 61.3%(222/362), P<0.05]. There was no statistically significant difference in the use of ACEI/ARB between the two groups [67.4%(411/610) vs 62.4%(226/362), P>0.05]. At one-year follow-up, the use of ACEI/ARB in outpatient patients decreased [63.5%(360/567) vs 67.4%(411/610), P<0.05], the usage rate of aldosterone receptor antagonists in hospitalized patients decreased by [50.3%(165/328) vs 61.3%(222/362), P<0.05]. The one-year all-cause mortality rate of the two groups of patients was close to [6.7%(41/610) vs 9.4%(34/362), P=0.124], The hospitalization rate for heart failure in the outpatient group was lower than that of hospitalized patients [25.4%(155/610) vs 36.5%(132/362), P<0.05], but still>25.0%. Conclusions:Outpatient heart failure patients still have obvious symptoms and signs, and the prognosis is poor. The standardized management of outpatient heart failure patients cannot be ignored.